SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMELIZED SINGLE-CHAIN ANTIBODIES, AIMED TO ONCOTIC RECEPTORS CD47/ERBB2, INTENDED FOR THE THERAPY OF MALIGNANT NEOPLASMS Russian patent published in 2018 - IPC A61K39/395 C07K16/28 C07K16/30 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, in particular, to a therapeutic bifunctional agent that suppresses the expansion of cancer stem cells by blocking oncotic receptors CD47 and ERBB2. This agent consists of two fragments of VHH camelized antibodies, the first of which is able to recognize and selectively bind to CD47, and the second – to ERBB2. Fragments are linked together by a polypeptide linker (Gly₄Ser)₄ or another linker that allows VHH fragments to be space-separated in space in such a way as to ensure unhampered binding each of them to their protein target.

EFFECT: present invention makes it possible to increase the specificity, bioavailability, efficacy and selectivity of antibodies inhibiting the expansion of cancer stem cells, while reducing the effect on normal cells of the patient's body.

3 cl, 2 ex